{"id":16999,"date":"2024-07-19T10:03:34","date_gmt":"2024-07-19T08:03:34","guid":{"rendered":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/"},"modified":"2024-07-19T10:03:34","modified_gmt":"2024-07-19T08:03:34","slug":"a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia","status":"publish","type":"publications","link":"https:\/\/www.laborberlin.com\/en\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/","title":{"rendered":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia."},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"template":"","publications-categories":[7],"class_list":["post-16999","publications","type-publications","status-publish","hentry","publications-categories-haematologie-onkologie"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Labor Berlin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.laborberlin.com\\\/publications\\\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\\\/\",\"url\":\"https:\\\/\\\/www.laborberlin.com\\\/publications\\\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\\\/\",\"name\":\"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.laborberlin.com\\\/#website\"},\"datePublished\":\"2024-07-19T08:03:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.laborberlin.com\\\/publications\\\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.laborberlin.com\\\/publications\\\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.laborberlin.com\\\/publications\\\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.laborberlin.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.laborberlin.com\\\/#website\",\"url\":\"https:\\\/\\\/www.laborberlin.com\\\/\",\"name\":\"Labor Berlin\",\"description\":\"Competence of Charit\u00e9 and Vivantes.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.laborberlin.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/","og_locale":"en_US","og_type":"article","og_title":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin","og_url":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/","og_site_name":"Labor Berlin","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/","url":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/","name":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. - Labor Berlin","isPartOf":{"@id":"https:\/\/www.laborberlin.com\/#website"},"datePublished":"2024-07-19T08:03:34+00:00","breadcrumb":{"@id":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.laborberlin.com\/publications\/a-phase-i-trial-investigating-the-aurora-b-kinase-inhibitor-bi-811283-in-combination-with-cytarabine-in-patients-with-acute-myeloid-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.laborberlin.com\/en\/"},{"@type":"ListItem","position":2,"name":"A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia."}]},{"@type":"WebSite","@id":"https:\/\/www.laborberlin.com\/#website","url":"https:\/\/www.laborberlin.com\/","name":"Labor Berlin","description":"Competence of Charit\u00e9 and Vivantes.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.laborberlin.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.laborberlin.com\/en\/wp-json\/wp\/v2\/publications\/16999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.laborberlin.com\/en\/wp-json\/wp\/v2\/publications"}],"about":[{"href":"https:\/\/www.laborberlin.com\/en\/wp-json\/wp\/v2\/types\/publications"}],"wp:attachment":[{"href":"https:\/\/www.laborberlin.com\/en\/wp-json\/wp\/v2\/media?parent=16999"}],"wp:term":[{"taxonomy":"publications-categories","embeddable":true,"href":"https:\/\/www.laborberlin.com\/en\/wp-json\/wp\/v2\/publications-categories?post=16999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}